MAS825

DRUG10 trials

Sponsors

Novartis Pharma AG, Novartis Pharmaceuticals, The Hospital for Sick Children

Conditions

Atherosclerotic cardiovascular diseaseAutoinflammatory diseases including NLRC4-Gain of Function (GOF) also known as AIFEC (autoinflammation with infantile enterocolitis)COVID-19 Pneumonia, Impaired Respiratory FunctionClonal Hematopoiesis of Indeterminate Potential (CHIP)Coronary Heart DiseaseHealthy VolunteersHidradenitis SuppurativaNLRC4-GOF, AIFEC (Autoinflammation With Infantile Enterocolitis), XIAP Deficiency, CDC42 Mutations

Phase 1

A First-in-human Study to Investigate the Safety, Tolerability and Pharmacokinetics of MAS825 in Healthy Volunteers

CompletedNCT04665154

Novartis PharmaceuticalsHealthy Volunteers

Start: 2019-06-07End: 2022-08-03Updated: 2022-09-30

Phase 2

Study of Efficacy and Safety of Investigational Treatments in Patients With Moderate to Severe Hidradenitis Suppurativa

Active, not recruitingNCT03827798

Novartis PharmaceuticalsHidradenitis Suppurativa

Start: 2019-02-27End: 2026-12-11Updated: 2026-02-06

Study of Efficacy and Safety of MAS825 in Patients With COVID-19

CompletedNCT04382651

Novartis PharmaceuticalsCOVID-19 Pneumonia, Impaired Respiratory Function

Start: 2020-06-11End: 2021-04-21Updated: 2022-08-10

Study to Evaluate the Efficacy, Safety and Tolerability of MAS825 in Patients With Monogenic IL-18 Driven Autoinflammatory Diseases, Including NLRC4-GOF, XIAP Deficiency, or CDC42 Mutations

Active, not recruitingNCT04641442

Novartis PharmaceuticalsNLRC4-GOF, AIFEC (Autoinflammation With Infantile Enterocolitis), XIAP Deficiency, CDC42 Mutations

Start: 2020-12-18End: 2032-04-07Updated: 2026-03-03

A Study to Investigate the Efficacy, Safety, and Tolerability of DFV890 and MAS825 for Inflammatory Marker Reduction in Adult Participants With Coronary Heart Disease and Clonal Hematopoiesis of Indeterminate Potential (CHIP)

CompletedNCT06097663

Novartis PharmaceuticalsClonal Hematopoiesis of Indeterminate Potential (CHIP), Coronary Heart Disease

Start: 2024-02-15End: 2024-11-04Updated: 2026-03-27

A randomized, placebo-controlled, parallel-group, investigator- and participant-blinded Phase 2a study to investigate the efficacy, safety, and tolerability of DFV890 and MAS825 for inflammatory marker reduction in an adult population with coronary heart disease and Clonal Hematopoiesis of Indeterminate Potential (CHIP)

CompletedCTIS2023-506741-34-00

Novartis Pharma AGAtherosclerotic cardiovascular disease

Start: 2024-02-16End: 2024-11-04Target: 16Updated: 2024-10-25

A three-period multicenter study, with a randomized-withdrawal, double-blinded, placebo-controlled design to evaluate the clinical efficacy, safety and tolerability of MAS825 in patients with monogenic IL-18 driven autoinflammatory diseases, including NLRC4-GOF, XIAP deficiency, or CDC42 mutations.

Active, not recruitingCTIS2023-504419-34-00

Novartis Pharma AGAutoinflammatory diseases including NLRC4-Gain of Function (GOF) also known as AIFEC (autoinflammation with infantile enterocolitis), or Cell division control protein 42 homolog (CDC42) mutation., X-linked Inhibitor of Apoptosis Protein (XIAP) deficiency

Start: 2021-04-29Target: 7Updated: 2025-11-07

A Phase II Trial to Evaluate the Clinical Efficacy, Safety and Tolerability of MAS825 in Pediatric and Adult Participants With Still's Disease

RecruitingNCT07203001

Novartis PharmaceuticalsStill´s Disease

Start: 2025-11-03End: 2029-05-24Target: 20Updated: 2026-03-30

An open-label phase II trial to evaluate the clinical efficacy, safety and tolerability of MAS825 in pediatric and adult participants with Still’s disease

RecruitingCTIS2024-520208-25-00

Novartis Pharma AGStill’s disease

Start: 2026-01-15Target: 15Updated: 2026-01-26

Phase 3

A Single-patient Clinical Trial of MAS825 in a Patient With XIAP Deficiency

CompletedNCT06309823

The Hospital for Sick ChildrenX-linked Lymphoproliferative Syndrome Type 2 (XLP-2)

Start: 2023-02-08End: 2024-01-17Updated: 2024-03-13